Plus Therapeutics to Present at the ThinkEquity Conference
October 18, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
October 06, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month
October 05, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
October 04, 2022 07:15 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
September 22, 2022 07:00 ET
|
Plus Therapeutics Inc.
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186RNL targeted therapeutic development costs for leptomeningeal metastases...
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
September 12, 2022 07:00 ET
|
Plus Therapeutics Inc.
Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with...
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
September 06, 2022 07:00 ET
|
Plus Therapeutics Inc.
NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022 ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial AUSTIN, Texas, Sept. 06,...
Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate
August 29, 2022 07:00 ET
|
Plus Therapeutics Inc.
cGMP production of 186RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials AUSTIN, Texas, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Plus...
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
August 23, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...